human growth hormone 10IU is a human growth hormone that comes in a 10IU vial. This peptide is designed to be injected, and can help athletes enhance their performance in many ways. Some of the benefits athletes will notice are increased lean muscle mass, higher levels of fat-burning, strengthened bones, improved immune system, increased oxygen levels in the bloodstream, and increased overall performance when exercising while also having anti-aging properties. Buy HGH 10IU in our online store. It’s for sale at a good price, and can be shipped anywhere in the US by mail.
The product contains synthetic somatropin, which is made up of 191-amino acids which mimic the same growth hormones that the body produces naturally. It is recommended that athletes take between 2IU-4IU daily to be injected subcutaneously, usually around the stomach area. Users will generally want to take this peptide for a minimum cycle of 8 weeks to achieve results, with many taking it in cycles of up to 4-6 months at a time. It is common to stack this with other steroids to get the best possible results in your cycle.
Even though HGH is not an anabolic steroid, it still may have some side effects when using this performance enhancer. Due to the way that HGH reacts with estrogen, gynecomastia is still a potential side effect for users. Joint pain, numbness in the hands and feet, hyperthyroidism, and diabetes are all possible side effects if the drug is not taken in proper doses.
The dosage of HGH must be adjusted for the individual patient. The weekly dose should be divided into daily subcutaneous injections (administered preferably in the evening). HGH may be given in the thigh, buttocks, or abdomen; the site of SC injections should be rotated daily to help prevent lipoatrophy. Pediatric GHD Patients: Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended. Adult GHD Patients: The recommended dosage at the start of therapy is not more than 0.04 mg/kg/week. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to a maximum of 0.08 mg/kg/week, depending upon patient tolerance of treatment. Clinical response, side effects, and determination of age-adjusted serum IGF-I may be used as guidance in dose titration. This approach will tend to result in weight-adjusted doses that are larger for women compared with men and smaller for older and obese patients.
The HGH 3.33 mg presentation contains benzyl alcohol as a preservative. It should not be used in newborns increased mortality in patients with acute critical illnesses in intensive care units due to complications following open heart or abdominal surgery, multiple accidental traumas, or with acute respiratory failure. The safety of continuing growth hormone treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with growth hormone in patients having acute critical illnesses should be weighed against the potential risk.
Aimee
Sales Manager